Literature DB >> 12944557

Detection of sulfated glycoproteins in intestinal metaplasia: a comparison of traditional mucin staining with immunohistochemistry for the sulfo-Lewis(a) carbohydrate epitope.

K Bodger1, F Campbell, J M Rhodes.   

Abstract

BACKGROUND: Premalignant Barrett's oesophagus (BO) and gastric intestinal metaplasia (IM) show phenotypic variability. Incompletely differentiated sulfomucin rich gastric IM (type III) may have increased malignant potential. The types of sulfated oligosaccharide structures present in IM, BO, and colon have not been fully characterised. AIMS: To compare sulfo-Lewis(a) epitope tissue distribution with high iron diamine (HID) positive sulfomucin in metaplastic, dysplastic, and neoplastic tissues from oesophagus and stomach.
METHODS: Sections containing gastric IM or BO (some associated with dysplasia or adenocarcinoma) were stained by the HID/alcian blue (AB) method and immunohistochemically (antibody 91.9H) to detect sulfo-Lewis(a). Based on HID/AB staining, IM was subtyped into type I (complete) or types II and III (incomplete).
RESULTS: In total, 125 sections from 38 subjects were studied. Normal squamous oesophagus, normal gastric epithelium, and type I IM were negative for sulfomucin and sulfo-Lewis(a). In type II IM, occasional goblet cells were HID and sulfo-Lewis(a) positive, but sialomucin secreting (AB positive) columnar cells were sulfo-Lewis(a) negative. Type III IM was always sulfo-Lewis(a) positive. Sulfomucin staining in dysplasia and cancer was variable, but HID positive areas were always sulfo-Lewis(a) positive.
CONCLUSIONS: Sulfo-Le(a), which is expressed on colonic mucin, is invariably present on sulfomucins in gastric IM and BO. Its presence in incomplete variants of IM and its absence from type I IM emphasises the phenotypic differences between complete and incomplete forms of metaplasia. 91.9H immunostaining is useful in IM subtyping. Characterising the molecular basis of sulfo-Lewis(a) expression may help understand the process of aberrant differentiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12944557      PMCID: PMC1770063          DOI: 10.1136/jcp.56.9.703

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  37 in total

1.  DIAMINE METHODS FOR DIFFERENTIALING MUCOSUBSTANCES HISTOCHEMICALLY.

Authors:  S S SPICER
Journal:  J Histochem Cytochem       Date:  1965-03       Impact factor: 2.479

2.  Transitional mucosa of the large intestine.

Authors:  G T Williams
Journal:  Histopathology       Date:  1985-11       Impact factor: 5.087

3.  Mucin histochemistry of the columnar epithelium of the oesophagus (Barrett's oesophagus): a prospective biopsy study.

Authors:  M Peuchmaur; F Potet; D Goldfain
Journal:  J Clin Pathol       Date:  1984-06       Impact factor: 3.411

4.  Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres.

Authors:  M I Filipe; F Potet; W V Bogomoletz; P A Dawson; B Fabiani; P Chauveinc; A Fenzy; B Gazzard; D Goldfain; R Zeegen
Journal:  Gut       Date:  1985-12       Impact factor: 23.059

5.  The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma.

Authors:  J R Jass; M I Filipe
Journal:  Histochem J       Date:  1981-11

6.  Sulphomucin colonic type intestinal metaplasia and carcinoma in the stomach. A histochemical study of 115 cases obtained by biopsy.

Authors:  C B Huang; J Xu; J F Huang; X Y Meng
Journal:  Cancer       Date:  1986-04-01       Impact factor: 6.860

7.  Sulfated glycoprotein biosynthesis in human gastric mucosal biopsies.

Authors:  M Kakei; S Ohara; K Ishihara; K Goso; H Okabe; K Hotta
Journal:  Digestion       Date:  1984       Impact factor: 3.216

8.  Histochemical characterization of different types of intestinal metaplasia in gastric mucosa.

Authors:  D I Segura; C Montero
Journal:  Cancer       Date:  1983-08-01       Impact factor: 6.860

9.  Role of intestinal metaplasia in the histogenesis of gastric carcinoma.

Authors:  J R Jass
Journal:  J Clin Pathol       Date:  1980-09       Impact factor: 3.411

10.  Intestinal metaplasia and carcinomas of the human stomach: an immunohistological study.

Authors:  J Nardelli; J Bara; B Rosa; P Burtin
Journal:  J Histochem Cytochem       Date:  1983-03       Impact factor: 2.479

View more
  5 in total

1.  High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue.

Authors:  Alice Ly; Achim Buck; Benjamin Balluff; Na Sun; Karin Gorzolka; Annette Feuchtinger; Klaus-Peter Janssen; Peter J K Kuppen; Cornelis J H van de Velde; Gregor Weirich; Franziska Erlmeier; Rupert Langer; Michaela Aubele; Horst Zitzelsberger; Liam McDonnell; Michaela Aichler; Axel Walch
Journal:  Nat Protoc       Date:  2016-07-14       Impact factor: 13.491

2.  Evidence for a functional role of epigenetically regulated midcluster HOXB genes in the development of Barrett esophagus.

Authors:  Massimiliano di Pietro; Pierre Lao-Sirieix; Shelagh Boyle; Andy Cassidy; Dani Castillo; Amel Saadi; Ragnhild Eskeland; Rebecca C Fitzgerald
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-17       Impact factor: 11.205

3.  The Role of CDX2 in Intestinal Metaplasia Evaluated Using Immunohistochemistry.

Authors:  Byoung Hwan Lee; Nayoung Kim; Hye Seung Lee; Jung Mook Kang; Hyun Kyung Park; Hyun Jun Jo; Cheol Min Shin; Sang Hyub Lee; Young Soo Park; Jin Hyeok Hwang; Jin-Wook Kim; Sook-Hyang Jeong; Dong Ho Lee; Hyun Chae Jung; In Sung Song
Journal:  Gut Liver       Date:  2012-01-12       Impact factor: 4.519

Review 4.  The Interaction of the Gut Microbiota with the Mucus Barrier in Health and Disease in Human.

Authors:  Anthony P Corfield
Journal:  Microorganisms       Date:  2018-08-02

5.  mAb Das-1 recognizes 3'-Sulfated Lewis A/C, which is aberrantly expressed during metaplastic and oncogenic transformation of several gastrointestinal Epithelia.

Authors:  Jeffrey W Brown; Koushik K Das; Vasilios Kalas; Kiron M Das; Jason C Mills
Journal:  PLoS One       Date:  2021-12-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.